| Journal | Headache |
| Study Type | Randomized Trial |
| Population | Human participants |
This is the first randomized, double-blind, placebo-controlled trial examining vaporized cannabis for acute migraine treatment. The study provides rigorous clinical evidence that THC+CBD combination therapy significantly outperforms placebo for migraine pain relief, addressing a major gap in cannabinoid headache medicine.
This crossover RCT enrolled 92 adults who treated 247 separate migraine attacks with either 6% THC, 11% CBD, 6% THC + 11% CBD, or placebo cannabis flower via vaporization. The primary endpoint was pain relief at 2 hours post-dose. THC+CBD combination achieved 67.2% pain relief versus 4% with placebo, demonstrating statistical superiority. Individual cannabinoids showed less pronounced effects, suggesting potential synergy between THC and CBD for migraine treatment. The crossover design strengthened internal validity by having participants serve as their own controls.
“This study finally gives us controlled evidence for what many migraine patients have been reporting anecdotally for years. The clear superiority of the THC+CBD combination over individual cannabinoids reinforces my clinical observation that balanced formulations often outperform isolates for complex pain conditions.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Is vaporized cannabis effective for treating acute migraine attacks?
Yes, this randomized controlled trial found that a combination of 6% THC + 11% CBD was significantly superior to placebo for achieving pain relief (67.2% vs 4%). This represents the first rigorous clinical evidence supporting cannabis use for acute migraine treatment.
Which cannabis formulation works best for migraine – THC alone, CBD alone, or combined?
The study tested THC-dominant (6% THC), CBD-dominant (11% CBD), and combination (6% THC + 11% CBD) formulations. Based on the preliminary results showing 67.2% pain relief with the combination versus placebo, the THC + CBD formulation appears most promising, though complete comparative data between all formulations wasn’t fully presented.
How quickly does vaporized cannabis work for migraine pain?
The study assessed outcomes at 2 hours post-vaporization, which is the standard timeframe for evaluating acute migraine treatments. Vaporized delivery allows for rapid absorption, making it potentially suitable for acute migraine management when quick relief is needed.
Are there safety concerns with using cannabis for migraine treatment?
While this study’s safety data isn’t fully detailed in the summary, the crossover design with washout periods ≥1 week suggests the treatments were generally well-tolerated. However, patients should be aware of potential THC-related psychoactive effects and impairment that may affect driving or work activities.
Can cannabis be recommended as a first-line treatment for acute migraine?
While these results are promising, this appears to be the first randomized trial of cannabis for acute migraine. More research is needed before cannabis can be considered a first-line treatment, and it should be discussed with healthcare providers as part of a comprehensive migraine management plan, particularly in regions where medical cannabis is legal.
